reSee.it - Related Video Feed

CMS is currently offering a 20% bonus payout to hospitals that choose to use Remdesivir for Medicare aged patients. This drug is supposedly approved by the FDA and recommended by the NIH for COVID-19 treatment. However, it is known to cause kidney, heart, and liver failure. Hospitals are also being incentivized to PCR test every patient, regardless of the reason for their visit, in order to increase their numbers. The federal government pays a monthly bribe based on the percentage of PCR tests conducted. Hospitals receive a 20% bonus for every positive COVID-19 diagnosis, as well as for using Remdesivir and ventilating patients. Additionally, they receive further incentives for every COVID-19 death, amounting to $9,000 per case per month. The reasons behind these incentives remain unclear.

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug for 5 to 10 days in hospitals. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir is cardiotoxic and can cause death of heart cells. Despite this, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients. The World Health Organization published in April of last year that Remdesivir leads to increased acute kidney failure compared to other drugs. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

At home, it is recommended to treat viral replication by giving zinc and other remedies like hydroxychloroquine and ivermectin. However, the protocol followed was to provide no treatment until hospitalization. Once in the hospital, the treatment included ventilators and Remdesivir. It is claimed that Tony Fauci knew Remdesivir could be lethal, as it had caused harmful side effects in Ebola patients. The drug was then used in the pandemic, leading to kidney failure, heart failure, and organ collapse in those who died. The deaths were attributed to Remdesivir rather than the virus itself.

At home, it is recommended to treat viral replication by giving remedies like zinc and hydroxychloroquine, ivermectin, which reduce the spread of the disease. However, the protocol followed was different. No treatment was given until hospitalization, where ventilators and Remdesivir were used. It is known that Remdesivir can be harmful, as it caused side effects in Ebola patients. The drug was manipulated and made standard of care, leading to kidney failure, heart failure, and organ collapse in COVID-19 patients. The deaths during the pandemic were often attributed to kidney failure, which was caused by Remdesivir, not the virus itself.

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug in hospitals for 5 to 10 days. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir causes heart cell death and is cardiotoxic. However, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients, despite the World Health Organization's report in April of last year that it causes increased acute kidney failure. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

Before the pandemic, Dr. Fauci tested Remdesivir in an Ebola trial in Africa alongside four other drugs. However, the institutional review board (IRB), responsible for ensuring safety in clinical trials, intervened and removed Remdesivir from the trial due to its high fatality rate. Ebola typically kills 53% of those infected, but Remdesivir was causing even more deaths. It seems illogical to then administer this drug to individuals with a disease that has a much lower infection fatality rate of 1%. This decision appears questionable, but unfortunately, there is a history of similar actions being taken.

In 2011, 2012, and 2014, publications revealed that pseudouridine in mRNA shots could cause rapid cancers. Remdesivir, with a 53% mortality rate, was chosen by the FDA for COVID treatment despite being deemed unethical by the World Health Organization due to high death rates in Africa. This lethal drug was administered regardless of viral load, resulting in unnecessary deaths.

Patients are dying not from COVID, but from treatments like remdesivir causing organ failure. One person's mother died after being given remdesivir against their wishes, leading to organ shutdown. There was a financial incentive for hospitals to admit patients and put them on ventilators, resulting in unnecessary treatments and deaths.

Treating viral replication at home can be done with zinc and zinc-enhancing remedies like hydroxychloroquine and ivermectin. However, the protocol followed during the pandemic did not include these treatments. Instead, patients were only treated when they reached the hospital, where they were given ventilators and Remdesivir. It is known that Remdesivir can be lethal, as it caused kidney failure, heart failure, and organ collapse in many cases. The deaths during the pandemic were often attributed to kidney failure, which was actually caused by Remdesivir, not the virus itself.

Multiple studies, including one by the WHO, show that Remdesivir actually increases the risk of death. It's concerning that the federal government incentivizes hospitals to prescribe this toxic drug by offering a 20% bonus on the entire hospital bill for Medicare patients. Remdesivir costs around $3,000 per course. On the other hand, Ivermectin, as mentioned by Dr. Kory, reduces the risk of death by about 50%. Unfortunately, clinicians still use the wrong drug, Dexamethasone, in the wrong dose and for the wrong duration of time, simply because the NIH recommends it. The NIH and other agencies have disregarded multiple FDA-approved drugs that are both cost-effective and safe.

Speaker 0: There were four drugs that were being tested for Ebola. Remdesivir killed more people than placebo, and the data safety monitoring board had actually stopped the study where literally fifty three percent of Speaker 1: the patients died in the failed Ebola trial and was repurposed. It was a failed Ebola drug because it caused more harm than good in Ebola trials. It was still unpatent. It was Tony Fauci's drug of choice. The majority of hospital deaths were actually caused by Anthony Fauci because his NIH put out protocols that if the hospital systems adhered to, they got bonuses, big bonuses, lots of money, $3,000 per for putting an IV in of remdesivir. Boom. $3,000. But guess what? On top of the entire hospital stay, a 20% bonus, that could be hundreds of thousands of dollars. Speaker 0: The data was so overwhelming that remdesivir killed patients more so than placebo. The drug had to be stopped, and this was published in the New England Journal in the 2019. Speaker 2: What happened during COVID could not have happened without propaganda and censorship. And how do we overcome that propaganda and censorship? It's primarily through people not being willing to shut up.

At home, it is recommended to treat viral replication by giving zinc and other zinc-enhancing remedies like hydroxychloroquine and Ivermectin. However, the protocol followed by hospitals was to provide no treatment until admission, and then use ventilators and Remdesivir, which were known to be harmful. Tony Fauci was aware of the dangers of Remdesivir, as it caused lethal side effects in Ebola patients. Despite this, he manipulated a study to make Remdesivir the standard of care, resulting in kidney failure, heart failure, and organ collapse in COVID-19 patients. The deaths attributed to the virus were actually caused by Remdesivir.

We ended our previous episode with our COVID pyramid, build layer upon layer of lies, deceit, fraud, scandals. Now, by now you’re wondering how so many hospitals, doctors, and health care workers went along with all of the above. We have reached the capstone of our nauseating COVID pyramid. Pyramid. We shall name the capstone M and M, money and murder in hospitals. Shocking as it may sound, we’ve seen it before. Remember the unjust administering the killer drug midazolam in The UK as shown in part 19? Well, The US and many other countries had their own version called remdesivir. Here’s what happened. Hospitals were given incentives, as in money, for each and every COVID casualty. According to whistleblowers, investigative journalists, lawyers, and specialists, Hospitals in The US have been receiving $13,000 for every admitted COVID patient. There have been financial extras for every COVID test, for every positive outcome. If patients were treated with the only prescribed drug, remdesivir, the hospital received yet another bonus: 20% of the entire hospital bill of the patient. Then for every patient put on a ventilator, the hospital received $39,000. And if that patient officially died of COVID nineteen, they got yet another $13,000. That’s a lot of money. According to attorney Thomas Renz and CMS whistleblowers, the hospitals receive approximately $100,000 per COVID casualty if the above protocol was followed. Now the thing is, the American hospitals received this money in advance based on the COVID predictions, based on the flawed models of people like Brooks. If the hospitals didn’t actually meet those models, they had to pay that money back at a later stage. And we’re talking millions of dollars here. So what happened? Everybody who was admitted to a hospital, for instance because of a car accident or because of cancer or diabetes or kidney failure, everybody got a PCR test to start with. Due to the ridiculous amount of cycles, there was an abundance of false positives. False positives equals positives equals COVID patients equals money. Hence, the sunrise in COVID patients. Then remdesivir left its detrimental mark just like midazolam had done in The UK. You see, remdesivir is not a new drug. It was used in 2018 during the West African Ebola outbreak. It was known to have severe adverse effects such as kidney damage, liver damage, and even death. Yet in 2020, Anthony Fauci directed that remdesivir was to be the drug hospitals used to treat COVID nineteen, hence the incentives. So what happened next? Those poor patients only got worse, after which they were put on a ventilator. After all, that was yet another bonus of many thousands of dollars pouring straight into the pockets of the hospitals. Now the problem with ventilators is that the patient is put into an induced coma. His or her breathing is taken over by a machine that puts extra pressure on the lungs called barrow pressure. In the case of damaged lungs due to for instance pneumonia, those lungs will only get worse. The chances of that patient recovering, of being able to be taken off the ventilator and to start breathing by himself are very, very small. Combined with organ failure as a result of remdesivir, the chances of that patient ever leaving the hospital alive are next to nothing.

An experimental drug called remdesivir will be responsible for people's deaths. People diagnosed with COVID-19 in the hospital died between day one and day nine, specifically on day nine of a ten-day remdesivir treatment. Dr. Anthony Fauci claimed in May 2020 that remdesivir was found safe and effective in a drug trial in Africa a year earlier (02/2019), and hyperlinked the study in a memo to hospitals. However, in that trial, remdesivir killed 53% of people, and the safety board suspended its use at month six, deeming it too deadly and toxic for Ebola patients. Dr. Anthony Fauci and his department at the NIH funded the Ebola trial in Africa in 02/2019. Therefore, Fauci lied to Congress and the American people by claiming the drug was safe and effective against Ebola, when the safety board had deemed it too deadly and pulled it from the trial.

To treat viral infections at home, zinc and its enhancers, like hydroxychloroquine and ivermectin, should be used, as they significantly reduce disease spread. However, the established protocol delayed treatment until hospitalization, where patients received ventilators and remdesivir—both potentially lethal. Remdesivir had previously shown harmful effects in Ebola trials, leading to its discontinuation due to a high rate of severe side effects. Despite this, it became standard care during the pandemic, contributing to kidney failure, heart failure, and organ collapse in patients. Many who died were reported to have kidney failure, which was not caused by the virus but rather by the effects of remdesivir.

In 2018, remdesivir was described as one of the speaker’s “favorite targets,” but it was said to have been considered too unethical for Ebola clinical trials in Africa because a “53% kill rate” was published in medical journals. The speaker contrasts this with the choice made in April and May 2020 to use remdesivir as the drug of choice to treat COVID, stating that the drug was still treated as unacceptable for African trials due to the alleged 53% kill rate. The speaker claims that Anthony Fauci and Deborah Birx were present next to the president advocating for remdesivir, while stating that the World Health Organization said it was unethical to use. The speaker frames the issue as a lack of accountability and justice as long as financial interests determine what product is promoted, arguing that if the entity declaring a pandemic is also driven by financial interests, there is no possibility for accountability. The speaker also alleges that the decision-makers were formed out of the Eugenics Office at Carnegie Mellon in 1913, and that the same group established the World Health Organization in 1953. The speaker asserts that this group was making the decision in 2020 regarding remdesivir and says they have a problem with eugenics.

CMS is currently offering a 20% bonus payout to hospitals that choose to use remdesivir for all Medicare aged patients. This drug is supposedly approved by the FDA and recommended by the NIH for COVID-19 treatment. However, it is known to cause kidney, heart, and liver failure. Hospitals are also being incentivized to PCR test every patient, regardless of the reason for their visit, and are paid a bribe for the percentages of positive COVID-19 diagnoses. Additionally, hospitals receive a 20% bonus for using remdesivir, ventilating patients, and for every COVID-19 death, earning up to $9,000 per case per month. The reasons behind these incentives remain unclear.

Treating viral infections at home can be done by providing remedies that inhibit viral replication, such as zinc and substances that enhance zinc like hydroxychloroquine and ivermectin. However, the protocol followed during the pandemic did not include these treatments. Instead, patients were only treated once they reached the hospital, where they were given ventilators and Remdesivir. It is known that Remdesivir can be lethal, as it caused kidney failure, heart failure, and organ collapse in many cases. The deaths attributed to the virus were often a result of Remdesivir rather than the virus itself.

Remdesivir, one of four drugs tested for Ebola, allegedly killed more people than the placebo, leading the Data Safety Monitoring Board to halt the study. According to the transcript, 53% of patients died in the failed Ebola trial, but the drug was repurposed. It is claimed that Remdesivir was Anthony Fauci's drug of choice, and that the NIH protocols, which provided hospitals with bonuses for using remdesivir, caused the majority of hospital deaths. Reportedly, hospitals received $3,000 for each remdesivir IV and a potential 20% bonus. The data allegedly showed that remdesivir killed more patients than the placebo, resulting in the drug trial being stopped. One speaker stated that it is inexplicable that remdesivir became the standard of care, and that doctors seemingly shut off their brains and followed directions from above without questioning the use of remdesivir in every hospitalized patient.

A fifth Remdesivir trial, sponsored by the US Army Medical Research and Development Command out of Fort Detrick, Maryland, has no publicly available findings. This is in contrast to four NIAID-sponsored trials that present Remdesivir in a minimally positive light, despite methodological questions. A military whistleblower revealed that, from March 2020 to March 2024, 941 people in the wider military community were administered Remdesivir, and 601 of them died, representing a 64% death rate. The cause of these deaths is unknown, and it is unclear if Remdesivir was a factor. Questions are raised about the Department of Defense's transparency regarding this information.

Remdesivir, also known as "run death is near," played a key role in creating the illusion of a deadly pandemic. Doctors were told COVID-19 causes pneumonia and kidney failure. The hospital protocol involved renal and internal medicine consults, screening patients for kidney issues due to remdesivir's potential kidney damage. They monitored kidney function and were supposed to stop the drug if function declined. Remdesivir-induced kidney injury led to fluid buildup, often misdiagnosed as COVID-19 pneumonia. This, followed by ventilation and more drugs, became a deadly cycle. The increase in acute kidney injury deaths coincided with the rollout of the new tech bonus and later, the vaccine rollout in 2021, with unvaccinated patients possibly targeted for these protocols.

Pfizer knew their failed coronavirus modifications were dangerous, causing heart issues and death in animals. There is extensive literature, including patents and scientific publications, showing that they knew the heart was the target. The mRNA shots using pseudo uridine were known to generate tumors and rapid cancers. Remdesivir, with a 53% mortality rate, was chosen by the FDA as a COVID treatment, despite being deemed unethical by the World Health Organization due to its high death rate. The definition of adverse events was changed to exclude any causal link, allowing them to deny any negative effects. Data on these injections won't be published for another four and a half years.

Patients were desperate for ivermectin as their loved ones died, but the focus shifted to remdesivir, a previously failed Ebola drug. By November 2020, the World Health Organization advised against its use, citing ineffectiveness and potential kidney and liver damage. The European Society of Critical Care supported this stance. Despite the warnings, the U.S. Health and Human Services incentivized hospitals with a 20% bonus for administering remdesivir, leading to widespread use. It failed to reduce mortality and caused serious injuries, with some patients dying as a result. In May 2022, the WHO reaffirmed its initial decision, stating that remdesivir should never have been used.

I've stated since May 2020 that remdesivir will result in at least 30% death in those who receive it in the hospital. I had data pulled for Medicare patients in New York, and found that 26.9% of those who received remdesivir died. As of October 2020, the cardiovascular toxicology journal found that remdesivir causes death of heart cells and can lead to cardiac arrest. Yet, in December, the NIH decided to update all guidelines for treatment drugs allowed for COVID-19, and remdesivir was the only FDA-approved drug for hospitalized Americans, despite the WHO publishing that it causes increased acute kidney failure. As of January of this year, the FDA extended an emergency use authorization, making remdesivir the only authorized medication that can be administered to newborns to 18-year-olds.

Conflicts and controversies surrounding remdesivir are significant. In November 2020, the World Health Organization conducted a comprehensive study and advised against using remdesivir in hospitals due to its association with death and kidney and liver injuries. Despite this, the U.S. incentivizes its use by offering hospitals a 20% bonus on the total bill if remdesivir is administered. As a doctor, I find it troubling that while other medications do not provide such financial incentives, the use of remdesivir can lead to substantial additional costs for hospitals, contradicting the WHO's recommendations. This situation highlights a serious disconnect in medical decision-making.